ASTH vs ALHC vs CLOV vs OSCR vs WELL

For growth investors, Astrana Health, Inc.

(ASTH) is the stronger pick with 56. 4% revenue growth year-over-year, versus 27. 5% for Oscar Health, Inc. (OSCR). Astrana Health, Inc. (ASTH) offers the better valuation at 78. 4x trailing P/E (29. 1x forward), making it the more compelling value choice. Analysts rate Astrana Health, Inc. (ASTH) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Astrana Health, Inc.

(ASTH) is the cheapest at 78. 4x versus Welltower Inc. at 153. 3x. On forward P/E, Astrana Health, Inc. is actually cheaper at 29. 1x.

Over the past 5 years, Welltower Inc.

(WELL) delivered a total return of +202. 3%, compared to -67. 3% for Clover Health Investments, Corp. (CLOV). Over 10 years, the gap is even starker: ASTH returned +614. 5% versus CLOV's -72. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Welltower Inc.

(WELL) is the lower-risk stock at 0. 13β versus Oscar Health, Inc. 's 1. 84β — meaning OSCR is approximately 1283% more volatile than WELL relative to the S&P 500. On balance sheet safety, Oscar Health, Inc. (OSCR) carries a lower debt/equity ratio of 44% versus 193% for Astrana Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Astrana Health, Inc.

(ASTH) is pulling ahead at 56. 4% versus 27. 5% for Oscar Health, Inc. (OSCR). On earnings-per-share growth, the picture is similar: Alignment Healthcare, Inc. grew EPS 99. 4% year-over-year, compared to -1865. 9% for Oscar Health, Inc.. Over a 3-year CAGR, OSCR leads at 41. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Welltower Inc.

(WELL) is the more profitable company, earning 8. 8% net margin versus -4. 4% for Clover Health Investments, Corp. — meaning it keeps 8. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: WELL leads at 3. 3% versus -4. 4% for CLOV. At the gross margin level — before operating expenses — WELL leads at 39. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Astrana Health, Inc.

(ASTH) trades at 29. 1x forward P/E versus 140. 9x for Alignment Healthcare, Inc. — 111. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ALHC: 36. 1% to $24. 83.

In this comparison, WELL (1.

3% yield), ASTH (0. 4% yield) pay a dividend. ALHC, CLOV, OSCR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Welltower Inc.

(WELL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 13), 1. 3% yield, +223. 1% 10Y return). Oscar Health, Inc. (OSCR) carries a higher beta of 1. 84 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (WELL: +223. 1%, OSCR: -40. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ASTH (Healthcare) and ALHC (Healthcare) and CLOV (Healthcare) and OSCR (Healthcare) and WELL (Real Estate)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

WELL pays a dividend while ASTH, ALHC, CLOV, OSCR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.